Your account is not claimed yet. You can sign up with ORCID to claim your account.

Kenneth K W To (K K W To)

Years Active: 2019-2023
Publications (10 Years): 6

Chinese University of Hong Kong

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Chinese University of Hong Kong

Hong Kong

Associate Professor :: School of Pharmacy

Publications

Kenneth K W To, Enming Xing, Ross C Larue, Pui-Kai Li
BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications. Molecules (Basel, Switzerland) 28 (7) (2023)
Kenneth K W To, William Chi Shing Cho
Drug Repurposing to Circumvent Immune Checkpoint Inhibitor Resistance in Cancer Immunotherapy. Pharmaceutics 15 (8) (2023)
Kenneth K W To, James C H Chow, Ka-Man Cheung, William C S Cho
Circumvention of Gefitinib Resistance by Repurposing Flunarizine via Histone Deacetylase Inhibition. ACS pharmacology & translational science 6 (10) (2023)
Kenneth K W To, William Chi Shing Cho
An overview of rational design of mRNA-based therapeutics and vaccines. Expert opinion on drug discovery 16 (11) (2021)
K G Yang, Wayne Yuk Wai Lee, Alec Lik-Hang Hung, M F Tang, X Li, Alice Pik-Shan Kong, Ting-Fan Leung, Patrick Shu-Hang Yung, Kenneth K W To, Jack Chun-Yiu Cheng, Tsz-Ping Lam
Association of serum 25(OH)Vit-D levels with risk of pediatric fractures: a systematic review and meta-analysis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 32 (7) (2021)
Winnie Fong, Kenneth K W To
Drug repurposing to overcome resistance to various therapies for colorectal cancer. Cellular and molecular life sciences : CMLS 76 (17) (2019)

Kenneth K W To.css-eqlu8i{font-size:small;padding-left:4px;} (K K W To)